The present invention is directed to novel thalidomide derivative compoundsthat have activity as anti-angiogenic compounds. More particularly thecompounds have the general structure: where R1 is selected from the groupconsisting of H, halo, alkyl, haloalkyl, -NH2, hydroxy and alkoxy; R2 isselected from the group consisting of optionally substituted bicyclic,optionally substituted aryl, and R6 is H, or C1-C8 alkyl; R19 is optionallysubstituted aryl; and m is 0-6.